Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Current Assets (2023 - 2026)

MBX Biosciences has reported Current Assets over the past 4 years, most recently at $448.5 million for Q1 2026.

  • Quarterly results put Current Assets at $448.5 million for Q1 2026, up 83.62% from a year ago — trailing twelve months through Mar 2026 was $448.5 million (up 83.62% YoY), and the annual figure for FY2025 was $381.5 million, up 42.75%.
  • Current Assets reached $448.5 million in Q1 2026 per MBX's latest filing, up from $381.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $448.5 million in Q1 2026 and bottomed at $83.5 million in Q4 2023.
  • Median Current Assets over the past 4 years was $274.2 million (2024), compared with a mean of $291.6 million.
  • The largest annual shift saw Current Assets skyrocketed 220.24% in 2024 before it surged 41.37% in 2025.
  • Over 4 years, Current Assets stood at $83.5 million in 2023, then surged by 220.24% to $267.3 million in 2024, then surged by 42.75% to $381.5 million in 2025, then grew by 17.56% to $448.5 million in 2026.
  • Business Quant data shows Current Assets for MBX at $448.5 million in Q1 2026, $381.5 million in Q4 2025, and $397.5 million in Q3 2025.